First European implantable BCI company with FDA-approved* clinical trial in the US.
Continuous neural data streaming enables AI-powered therapy optimization in real-time, with seamless wireless communication across all system components.
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for CorTec’s Brain Interchange™ system. The designation covers the use of direct cortical electrical stimulation to support motor recovery in people living with chronic stroke-related impairments.
Stronger Motor Recovery in 6 Weeks Than in the Entire Previous Year
Therapeutic Effect Persists After Stimulation Stops
Stable Wireless Operation for 6+ Months
CorTec’s BCI platform combines real-time signal processing with targeted brain stimulation through 32 implanted channels. Our closed-loop system continuously monitors neural activity and adapts stimulation parameters in milliseconds – enabling precise, responsive treatment.
CorTec is preparing its next funding round to accelerate pivotal trials, expand indications, and drive toward commercialization. We welcome conversations with aligned investors.
Total BCI Market Opportunity
Stroke Survivors Worldwide
Scientific Publications with CorTec Technology
Research Institutes Served with CorTec Technology
